La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Cargo Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Cargo Therapeutics..

Cargo Therapeutics (NASDAQ:CRGX) Azioni, Catena delle Opzioni

Cargo Therapeutics

Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.

Cargo Therapeutics Inc

HC Wainwright &amp; Co. analyst Mitchell Kapoor maintains Rallybio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLYB#NASDAQ">RLYB</a>) with a Buy and lowers the price target from $6 to $5.

News

Price Target

Analyst Ratings

RLYB

HC Wainwright & Co. Maintains Buy on Rallybio, Lowers Price Target to $5

<a href="https://www.bloomberg.com/news/articles/2024-11-08/toyota-executive-lashes-out-at-us-regulations-promoting-ev-sales">https://www.bloomberg.com/news/articles/2024-11-08/toyota-executive-lashes-out-at-us-regulations-promoting-ev-sales</a>
&nbsp;
Toyota Motor Corp.'s North American chief operating officer criticized the US's policies promoting speedy adoption of electric vehicles, calling them "de facto mandates" out of sync with consumer demand.

Management

Global

'Toyota Executive Lashes Out At U.S. Regulations Promoting EV Sales' - Bloomberg News

Needham analyst Chris Pierce maintains CarGurus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARG#NASDAQ">CARG</a>) with a Buy and raises the price target from $27 to $39.

CARG

Needham Maintains Buy on CarGurus, Raises Price Target to $39

Barclays analyst Benjamin Budish maintains Carlyle Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CG#NASDAQ">CG</a>) with a Overweight and raises the price target from $50 to $57.

Barclays Maintains Overweight on Carlyle Group, Raises Price Target to $57

HC Wainwright &amp; Co. analyst Arthur He reiterates Poseida Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>) with a Buy and maintains $20 price target.

Reiteration

PSTX

HC Wainwright & Co. Reiterates Buy on Poseida Therapeutics, Maintains $20 Price Target

Barclays analyst Jared Shaw maintains Synovus Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNV#NYSE">SNV</a>) with a Overweight and raises the price target from $56 to $64.

Barclays Maintains Overweight on Synovus Finl, Raises Price Target to $64

Motorola Solutions, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSI#NYSE">MSI</a>) reported better-than-expected third-quarter financial results and issued <a href="https://www.benzinga.com/quote/MSI/earnings">FY24 adjusted EPS guidance above estimates on Thursday.</a>
Motorola Solutions reported quarterly earnings of $3.74 per share which beat the analyst consensus estimate of $3.38 per share. The company reported quarterly sales of $2.79 billion which beat the analyst consensus estimate of $2.76 billion.
&#8220;Our third-quarter results were exceptional, with record Q3 revenue, earnings and cash flow,&#8221; said Greg Brown, chairman and CEO, Motorola Solutions. &#8220;We achieved strong growth across the board, and I&#8217;m pleased with the momentum of our business. As a result, we&#8217;re again raising our revenue and earnings expectations for the full year.&#8221;
Motorola Solutions shares gained 6.8% to trade at $501.80 on Friday.
These analysts made changes to their price targets on Motorola Solutions following earnings announcement.
<ul>
<li>Raymond James analyst Adam Tindle maintained Motorola with an Outperform and raised the price target from $425 to $515.</li>
<li>Barclays analyst Tim Long maintained the stock with an Overweight and raised the price target from $467 to $529.</li>
</ul>
Considering buying MSI stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="581" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08140602/image-95-1024x581.png" alt="" class="wp-image-638367" style="width:541px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08140602/image-95-1024x581.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08140602/image-95-300x170.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08140602/image-95-768x436.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08140602/image-95.png 1167w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/41820056/how-to-earn-500-a-month-from-nvidia-stock-after-trump-win">How To Earn $500 A Month From Nvidia Stock After Trump Win</a></li>
</ul>

Earnings

Markets

Trading Ideas

These Analysts Raise Their Forecasts On Motorola Solutions Following Q3 Earnings

HC Wainwright &amp; Co. analyst Robert Burns reiterates Tango Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNGX#NASDAQ">TNGX</a>) with a Buy and maintains $13 price target.

TNGX

HC Wainwright & Co. Reiterates Buy on Tango Therapeutics, Maintains $13 Price Target

Barclays analyst Julian Mitchell maintains Rockwell Automation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>) with a Underweight and raises the price target from $245 to $255.

Barclays Maintains Underweight on Rockwell Automation, Raises Price Target to $255

WIIM

Canopy Growth shares are trading lower. The company reported Q2 financial results.

<a href="https://www.devdiscourse.com/article/technology/3150879-nhtsa-raises-concerns-over-teslas-fsd-promotion">https://www.devdiscourse.com/article/technology/3150879-nhtsa-raises-concerns-over-teslas-fsd-promotion</a>
The National Highway Traffic Safety Administration (NHTSA) voiced concerns about Tesla's social media messaging concerning its Full Self-Driving (FSD) software.
NHTSA's worry stems from Tesla's implications that their FSD can be used as a robotaxi, negating the need for constant driver attention. This issue has elevated in importance following an investigation the agency initiated in October into 2.4 million Tesla vehicles equiped with FSD software.
The inquiry came after four reported accidents, including a fatal crash this year. In an email from May 14 released publicly, the NHTSA criticized Tesla's social media announcements for potentially misleading the public into viewing the FSD as anything other than a driver assist system demanding vigilant supervision and occasional driver intervention.

Legal

TSLA

"The National Highway Traffic Safety Administration Expressed Concerns Regarding Tesla's Social Media Posts That Imply Its Full Self-Driving Software Can Function As A Robotaxi Without Driver Supervision. This Comes After The NHTSA Opened An Investigation Into Tesla's FSD Software Following Four Collisions, Including A Fatal Crash In 2023." - Dev Discourse

HC Wainwright &amp; Co. analyst Robert Burns maintains Relay Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLAY#NASDAQ">RLAY</a>) with a Buy and raises the price target from $19 to $20.

RLAY

HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Raises Price Target to $20

MNMD

Mind Medicine shares are trading higher after the company reported better-than-expected Q3 EPS results.

PRQR

ProQR Therapeutics shares are trading higher afer HC Wainwright & Co. maintained a Buy rating on the stock and raised its price target from $5 to $10.

Needham analyst Laura Martin reiterates Outbrain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OB#NASDAQ">OB</a>) with a Buy and maintains $6 price target.

Needham Reiterates Buy on Outbrain, Maintains $6 Price Target

Over the past 24 hours, Injective's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/inj/usd">INJ</a>) price rose 4.88% to $22.66. This continues its positive trend over the past week where it has experienced a 20.0% gain, moving from $18.77 to its current price. As it stands right now, the coin's all-time high is $52.62. 
The chart below compares the price movement and volatility for Injective over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1731092546_0.png" alt="price_chart" />
The trading volume for the coin has increased 55.0% over the past week while the overall circulating supply of the coin has increased 0.0% to over 97.73 million. The current market cap ranking for INJ is #50 at $2.21 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1731092546_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Movers

$INJ

Cryptocurrency Injective Rises More Than 4% In 24 hours

ACHR

Archer Aviation shares are trading higher after the company reported better-than-expected Q3 EPS results.

Barclays analyst Adrienne Yih maintains Ralph Lauren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RL#NYSE">RL</a>) with a Overweight and raises the price target from $200 to $257.

Barclays Maintains Overweight on Ralph Lauren, Raises Price Target to $257

ESPR

Esperion Therapeutics shares are trading higher. The stock may be moving on continued strength after reporting better-than-expected Q3 financing results yesterday. Also, HC Wainwright & Co. reiterated a Buy rating on the stock.

Over the past 24 hours, dogwifhat's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">WIF</a>) price has fallen 3.22% to $2.31. This is opposite to its positive trend over the past week where it has experienced a 2.0% gain, moving from $2.25 to its current price. 
The chart below compares the price movement and volatility for dogwifhat over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1731092476_0.png" alt="price_chart" />
The trading volume for the coin has increased 63.0% over the past week. while the overall circulating supply of the coin has decreased 0.21% This puts its current circulating supply at an estimated 100.0% of its max supply, which is 998.93 million. The current market cap ranking for WIF is #48 at $2.31 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1731092477_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$WIF

Cryptocurrency dogwifhat Down More Than 3% Within 24 hours

CARGO Therapeutics, Inc. (CRGX) has received a new Buy rating, initiated by Piper Sandler analyst, Biren Amin. Biren Amin has given his Buy rating ...

CARGO Therapeutics' Promising Pipeline and Market Potential Justify Buy Rating

CARGO Therapeutics, Inc. (CRGX) has received a new Buy rating, initiated by Chardan Capital analyst, Geulah Livshits. Geulah Livshits has given his...

Buy Rating Affirmed for CARGO Therapeutics on Promising CAR-T Advancements and Strategic Positioning

In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on CARGO Therapeutics, Inc. (CRGX – Research Report), with a ...

CARGO Therapeutics: Strong Buy on Robust Financials and Promising Clinical Trials

CARGO Therapeutics GAAP EPS of -$1.02

In a report released today, Asthika Goonewardene from Truist Financial reiterated a Buy rating on CARGO Therapeutics, Inc. (CRGX – Research Report)...

Truist Financial Reaffirms Their Buy Rating on CARGO Therapeutics, Inc. (CRGX)

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Cargo Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/crgx-stock-quote/">CRGX</a>) just reported results for the second quarter of 2024.<ul><li>Cargo Therapeutics reported earnings per share of -$1.02. This was above the analyst estimate for EPS of -$1.06.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/crgx-stock-earnings-cargo-therapeutics-for-q2-of-2024/">CRGX Stock Earnings: Cargo Therapeutics Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CRGX Stock Earnings: Cargo Therapeutics Beats EPS for Q2 2024

Piper Sandler analyst Biren Amin maintained a Buy rating on CARGO Therapeutics, Inc. (CRGX – Research Report) today and set a price target of $34.0...

Piper Sandler Reaffirms Their Buy Rating on CARGO Therapeutics, Inc. (CRGX)

In a report released today, Brian Cheng from J.P. Morgan reiterated a Buy rating on CARGO Therapeutics, Inc. (CRGX – Research Report), with a price...

Firi-cel's Promising Outlook and Undervalued Potential Drive Buy Rating for CARGO Therapeutics

CARGO Therapeutics (CRGX) announced that its first abstract on CRG-023 will be presented as a poster at the upcoming 66th American Society of Hemat...

Cargo Therapeutics announces ASH 2024 abstract on CRG-023

CRGX

Press Releases

CARGO Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

CARGO Therapeutics Names Kapil Dhingra, M.B.B.S., to Board of Directors

CARGO Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Biotech

General

CARGO Therapeutics Announces $110.0 Million Private Placement Equity Financing

CARGO Therapeutics to Participate in Upcoming Investor Conferences

Health Care

CARGO Therapeutics Adds Experienced Biopharma Executive to Board of Directors with the Appointment of Jane Pritchett Henderson as Independent Director

CARGO Therapeutics Announces Phase 1 Clinical Study of Firi-cel CAR T-Cell Therapy Published in The Lancet

CARGO Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

CARGO Therapeutics Announces ASH 2024 Abstract on CRG-023, a Tri-specific CAR T, Highlighting Innovative Construct Design and Durable Anti-B-Cell Lymphoma Activity

Comments

Cargo Therapeutics

Cargo Therapeutics (CRGX) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO